The present invention relates to new co-crystals of non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the class of phenylpropionic or phenylacetic acid derivatives. Lysine and Gabapentin, to their pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.
The present invention relates to C5aR inhibitor compounds, preferably C5aR noncompetitive allosteric inhibitors, useful in the treatment and/or prevention of chemotherapy-induced iatrogenic pain (CIIP).
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or Auris interna target areas, or via perfusion into the auris media and/or Auris interna structures.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
6.
RALOXIFENE FOR USE IN THE TREATMENT OF SARS-COV-2 VARIANTS INFECTIONS
ISTITUTO NAZIONALE MALATTIE INFETTIVE LAZZARO SPALLANZANI (Italy)
Inventor
Beccari, Andrea Rosario
Iaconis, Daniela
Talarico, Carmine
Manelfi, Candida
Scorzolini, Laura
Bordi, Licia
Matusali, Giulia
Nicastri, Emanuele
Abstract
The present invention relates to Raloxifene or a pharmaceutically acceptable salt thereof for use in the treatment of an infection caused by one or more variants of SARS-CoV-2 in a subject.
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
The present invention relates to a composition containing plant extracts of Berberis aristata DC., Olea Europea L., Trigonella foenum-graecum L., Cynara scolymus L. and a mixture of phytosterols extracted from Helianthus annuus L., and the use thereof in the treatment of dyslipidaemias.
Inhibitor compounds of type 2 iodothyronine deiodinase (D2) are described for use in the therapeutic treatment of muscle wasting and/or in a muscle and/or skin regenerative therapeutic method. A pharmaceutical composition comprising a type 2 iodothyronine deiodinase (D2) inhibitor compound in a pharmaceutically acceptable vehicle, as well as in combination with optional excipients, diluents and adjuvants, is also described.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
9.
METHOD OF OBTAINING RECOMBINANT HUMAN BRAIN-DERIVED NEUROTROPHIC FACTOR
The present invention relates to a human proBDNF mutein and to a method of recombinantly producing a biologically active human brain-derived neurotrophic factor (BDNF).
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A method of predicting cocrystal formation is described comprising forming a data set with active pharmaceutical ingredients (APIs) and coformers comprising a training set including a plurality of pairs of the selected active pharmaceutical ingredient and a selected coformer, wherein the training set comprises pairs known to form cocrystals or known not to form cocrystals; a test set including at least one pair of the selected active pharmaceutical ingredient and a selected coformer, wherein cocrystal formation of pairs is unknown; the method includes determining a plurality of descriptors for each pair of the training set and of the test set, being miscibility descriptors, possibility of hydrogen bonding descriptors, and shape and size descriptors for each pair of the training set and of the test set; providing descriptors as input data and obtaining outcome from partial least squares discriminant analysis (PLS-DA), Random Forest (RF), and Neural Networks (NN) models as a constructed model space where each pair of the training set and of the test set are characterized by a respective position in the constructed model space; and determining a probability (or a likelihood ratio) of the pairs of the test set to form cocrystals based on the position of the pairs of the test set in the constructed model space.
The present invention relates to a stable monohydrate of compound DF2755A, to a process for its manufacture, to its pharmaceutical compositions and medical uses. The monohydrate of compound DF2755A of the present invention is physically, chemically and optically stable, thus particularly advantageous for pharmaceutical applications.
A deformable container for dispensing a medical substance comprising a body defining an internal volume configured to receive a fluid substance, said body comprising a filling access configured to receive the fluid substance, a dispensing outlet configured to dispense the fluid substance, a valve arranged at the filling access movable between an open configuration and a closed configuration. The body comprises an elastically deformable wall delimiting the internal volume. The disclosure further relates to a connecting accessory comprising a first coupling portion, configured to fluidly connect to the filling access of the deformable container, and a second coupling portion configured to fluidly connect to an internal compartment of a vial. The container and the connecting accessory are configurable in a coupled configuration wherein the connecting accessory is coupled to the filling access of the container, and the valve of the container is in the open configuration.
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
A61J 7/00 - Devices for administering medicines orally, e.g. spoonsPill counting devicesArrangements for time indication or reminder for taking medicine
13.
C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID
The invention relates to C5aR1 inhibitors for use in the prevention and/or treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
14.
CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID
The invention relates to CXCL8 inhibitors useful in the prevention and/or treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The present invention relates to the use of a C5aR1 inhibitor for the prevention or treatment of a hypersensitivity reaction (HSR) to a taxane in an individual.
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
18.
CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES
The present invention relates to nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of spasticity in a subject, wherein preferably said NGF or mutein is administered intranasally to said subject.
The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.
The present invention relates to a peptide, or derivative thereof, having length equal to or lower than (30) amino acids, and comprising any one of SEQ ID Nos. 2, 3, 9, 10, 13, 14, 15, 16, 17, 18, or a conservative variant thereof, for use as a medicament, preferably for use in the treatment of conditions associated to/caused by deficient angiogenesis or conditions beneficing from increased angiogenesis.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed herein are otic formulations and compositions comprising BDNF. These otic formulations and compositions allow for the delivery of BDNF to the inner ear for the treatment of otic diseases and disorders.
The present invention relates to brain derived nerve factor (BDNF) for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said BDNF is administered intranasally to said subject.
The present invention relates to nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said NGF is administered intranasally to said subject.
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention relates to a powder mixture of reparixin suitable to produce a reconstituted liquid suspension in an aqueous vehicle at the time of use.
The present invention relates to a pharmaceutical package comprising a plastic container and an aqueous formulations of nerve growth factor (NGF), in which at least the surface of the container in contact with the NGF aqueous formulation is made of particular polypropylenes (PPs), characterized by certain thermal properties and crystallinity. Advantageously said containers show a NGF adhesion significantly lower than that of siliconized glass or of other polypropylenes. It is thus possible to store aqueous formulations of NGF in less severe conditions, avoiding additional coating treatments to the containers and additives while keeping the NGF titer constant.
The present invention relates to a new co-crystal of Ketoprofen, Lysine and Gabapentin, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
33.
GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
The present invention relates to GPR120 agonists for use in the treatment of inflammatory bowel disease, in particular ulcerative colitis or Crohn's disease.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
C07D 333/02 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
34.
IL-8 INHIBITORS FOR USE IN THE TREATMENT OF SOME SARCOMAS
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (USA)
Inventor
Roberts, Ryan David
Brandolini, Laura
Abstract
The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1 /CXCR2 receptor inhibitors, useful in the treatment and/or prevention of some sarcomas, preferably in the treatment and/or prevention of osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof.
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
Object of the present invention is a drug delivery system comprising a decellularized corneal stroma scaffold having dispersed within and/or bound to its surface microparticles containing at least one pharmaceutically active molecule dispersed in a matrix having a composition consisting for at least 70% of polylactic co-glycolic acid (PLGA).
The present invention belongs to the technical field of drug synthesis. In particular, the present invention is related to a for preparing a salt of isocyclosporin A, in particular by transesterification of cyclosporin A into a salt of isocyclosporin A.
The present invention relates to isocyclosporin A, salts and ophthalmic compositions thereof for ophthalmic topical use in the prevention or treatment in an individual of an ophthalmic inflammatory and/or autoimmune disease, preferably selected from corneal and ocular surface inflammatory and/or autoimmune diseases and eyelid margin inflammatory diseases.
The present invention belongs to the technical field of drug synthesis. In particular, the present invention is related to a for preparing a salt of isocyclosporin A, in particular by transesterification of cyclosporin A into a salt of isocyclosporin A.
C07K 7/64 - Cyclic peptides containing only normal peptide links
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
40.
CO-CRYSTAL OF GABAPENTIN, KETOPROFEN AND LYSINE, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE
The present invention relates to a new co-crystal of Gabapentin, Ketoprofen and Lysine, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
The present invention relates to a synergistic admixture of Gabapentin and Ketoprofen, preferably Ketoprofen Lysine, to a pharmaceutical composition comprising said admixtures and to the use of said admixtures or pharmaceutical compositions in the treatment of acute or chronic pain, in particular in the treatment of neuropathic or inflammatory pain.
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
The present invention relates to new co-crystals of non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the class of phenylpropionic or phenylacetic acid derivatives, Lysine and Gabapentin, to their pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 57/30 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07C 57/58 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
C07C 59/64 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
C07C 59/68 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
44.
CO-CRYSTALS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, LYSINE AND GABAPENTIN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE
The present invention relates to new co-crystals of non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the class of phenylpropionic or phenylacetic acid derivatives, Lysine and Gabapentin, to their pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07C 57/30 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
C07C 57/58 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
C07C 59/64 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
C07C 59/68 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
45.
GROWTH FACTOR FORMULATION FOR CONDITION ASSOCIATED WITH OTIC EVENT
Disclosed herein are otic formulations and compositions comprising growth factors. These otic formulations and compositions allow for the delivery of the growth factor to the outer, middle, and/or inner ear for the treatment of otic diseases and disorders.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
46.
CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
The present invention relates to a combination of a CXCL8 activity inhibitor and a corticosteroid, and a pharmaceutical composition thereof, for use in the treatment of corticosteroid-insensitive asthma as well as to a method for treating corticosteroid-insensitive asthma by administration of said pharmaceutical composition.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
47.
CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF CANCER-RELATED FATIGUE
The present invention relates to a CXCL8 inhibitor and a pharmaceutical composition thereof, for use in the prevention or treatment of cancer-related fatigue in a cancer patient.
ISTITUTO NAZIONALE MALATTIE INFETTIVE LAZZARO SPALLANZANI (Italy)
Inventor
Beccari, Andrea Rosario
Iaconis, Daniela
Talarico, Carmine
Manelfi, Candida
Scorzolini, Laura
Bordi, Licia
Matusali, Giulia
Nicastri, Emanuele
Abstract
The present invention relates to Raloxifene or a pharmaceutically acceptable salt thereof for use in the treatment of an infection caused by one or more variants of SARS-CoV-2 in a subject.
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
ISTITUTO NAZIONALE MALATTIE INFETTIVE LAZZARO SPALLANZANI (Italy)
Inventor
Beccari, Andrea Rosario
Iaconis, Daniela
Talarico, Carmine
Manelfi, Candida
Scorzolini, Laura
Bordi, Licia
Matusali, Giulia
Nicastri, Emanuele
Abstract
The present invention relates to Raloxifene or a pharmaceutically acceptable salt thereof for use in the treatment of an infection caused by one or more variants of SARS-CoV-2 in a subject.
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Computer software relating to the medical field; computer
software for use in medical decision support systems;
virtual reality software for medical teaching; virtual
screening software; collaboration software platforms
[software]; computer software platforms, recorded or
downloadable; computer software applications, downloadable;
artificial intelligence software for healthcare. Platforms for artificial intelligence as software as a
service [SaaS]; providing artificial intelligence computer
programs on data networks; research in the field of
artificial intelligence; design and development of computer
software for use with medical technology; design and
development of virtual screening software; design and
development of virtual reality software for teaching
medicine.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Computer software relating to the medical field; computer
software for use in medical decision support systems;
virtual reality software for medical teaching; virtual
screening software; collaboration software platforms
[software]; computer software platforms, recorded or
downloadable; computer software applications, downloadable;
artificial intelligence software for healthcare. Platforms for artificial intelligence as software as a
service [SaaS]; providing artificial intelligence computer
programs on data networks; research in the field of
artificial intelligence; design and development of computer
software for use with medical technology; design and
development of virtual screening software; design and
development of virtual reality software for teaching
medicine.
53.
CO-CRYSTAL OF KETOPROFEN AND ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
The present invention refers to a eco-crystal of Ketoprofen Lysine named Form 4, a pharmaceutical composition comprising said co-crystal, a process for its preparation and to its use in the treatment of pain and Inflammatory diseases.
Inhibitor compounds of type 2 iodothyronine deiodinase (D2) are described for use in the therapeutic treatment of muscle wasting and/or in a muscle and/or skin regenerative therapeutic method. A pharmaceutical composition comprising a type 2 iodothyronine deiodinase (D2) inhibitor compound in a pharmaceutically acceptable vehicle, as well as in combination with optional excipients, diluents and adjuvants, is also described.
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable computer software for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; downloadable computer software for use by doctors and other medical professionals in capturing, tracking, reporting, analyzing health data in the field of medical decision support systems; downloadable virtual reality software for medical teaching, specifically, for granting user access to courses of instruction in the medical field; downloadable virtual screening software, specifically, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, and facilitates proof-of-concept testing in selected pre-clinical models; downloadable collaboration software platforms for use in database management in the field of medicine; downloadable computer software platforms for identifying new drugs in the nature of software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; downloadable artificial intelligence software for identifying new drugs in the nature of software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models in the field of healthcare Software as a service (SAAS) services featuring software platforms using artificial intelligence for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; providing temporary use of online, non-downloadable artificial intelligence computer programs accessible via data networks for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; research in the field of artificial intelligence; design and development of computer software for operating medical technology in the nature of software for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; design and development of virtual screening software; design and development of virtual reality software for teaching medicine
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable computer software for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; downloadable computer software for use by doctors and other medical professionals in capturing, tracking, reporting, analyzing health data in the field of medical decision support systems; downloadable virtual reality software for medical teaching, specifically, for granting user access to courses of instruction in the medical field; downloadable virtual screening software, specifically, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, and facilitates proof-of-concept testing in selected pre-clinical models; downloadable collaboration software platforms for use in database management in the field of medicine; downloadable computer software platforms for identifying new drugs in the nature of software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; downloadable artificial intelligence software for identifying new drugs in the nature of software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models in the field of healthcare Software as a service (SAAS) services featuring software platforms using artificial intelligence for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; providing temporary use of online, non-downloadable artificial intelligence computer programs accessible via data networks for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; research in the field of artificial intelligence; design and development of computer software for operating medical technology in the nature of software for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; design and development of virtual screening software; design and development of virtual reality software for teaching medicine
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Computer software relating to the medical field; Computer software for use in medical decision support systems; Virtual reality software for medical teaching; Virtual screening software; Collaboration software platforms [software]; Computer software platforms, recorded or downloadable; Computer software applications, downloadable; Artificial intelligence software for healthcare. Platforms for artificial intelligence as software as a service [SaaS]; Providing artificial intelligence computer programs on data networks; Research in the field of artificial intelligence; Design and development of computer software for use with medical technology; Design and development of virtual screening software; Design and development of virtual reality software for teaching medicine.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Computer software relating to the medical field; Computer software for use in medical decision support systems; Virtual reality software for medical teaching; Virtual screening software; Collaboration software platforms [software]; Computer software platforms, recorded or downloadable; Computer software applications, downloadable; Artificial intelligence software for healthcare. Platforms for artificial intelligence as software as a service [SaaS]; Providing artificial intelligence computer programs on data networks; Research in the field of artificial intelligence; Design and development of computer software for use with medical technology; Design and development of virtual screening software; Design and development of virtual reality software for teaching medicine.
59.
NOVEL PROTEIN AND NUCLEIC ACID SEQUENCES FOR COVID-19 VACCINES
The present invention relates to a mutated SARS-CoV-2 spike protein, a variant or fragment thereof or an mRNA or DNA encoding them for use in the prevention of COVID-19.
The present invention relates to a mutated SARS-CoV-2 spike protein, a variant or fragment thereof or an mRNA or DNA encoding them for use in the prevention of COVID-19.
A deformable container for dispensing a medical substance comprising a body defining an internal volume configured to receive a fluid substance, said body comprising a filling access configured to receive the fluid substance, a dispensing outlet configured to dispense the fluid substance, a valve arranged at the filling access movable between an open configuration and a closed configuration. The body comprises an elastically deformable wall delimiting the internal volume. The disclosure further relates to a connecting accessory comprising a first coupling portion, configured to fluidly connect to the filling access of the deformable container, and a second coupling portion configured to fluidly connect to an internal compartment of a vial. The container and the connecting accessory are configurable in a coupled configuration wherein the connecting accessory is coupled to the filling access of the container, and the valve of the container is in the open configuration.
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
A61J 7/00 - Devices for administering medicines orally, e.g. spoonsPill counting devicesArrangements for time indication or reminder for taking medicine
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/566 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol having an oxo group in position 17, e.g. oestrone
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/566 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol having an oxo group in position 17, e.g. oestrone
A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical products for the treatment of eye diseases;
pharmaceutical preparations for eyes for medical use;
pharmaceutical preparations for use in ophthalmology;
pharmaceutical substances for use in ophthalmology; medical
preparations for use in ophthalmology. Scientific and technological services and research relating
to the fields of ophthalmology and eye care and diseases;
provision of scientific information and medical research
information.
67.
C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES
The present invention relates to the use of a C5aR1 inhibitor for the prevention or treatment of a hypersensitivity reaction (HSR) to a taxane in an individual.
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to compositions comprising branched-chain amino acids (BCAA) and the amino acid L-Alanine and their use in the prevention and/or treatment of muscle wasting associated to pathological or age-related conditions.
The present invention relates to compositions comprising branched-chain amino acids (BCAA) and the dipeptide L-Alanyl-L-alanine and their use for improving the performance and recovery during physical activity and for the prevention and/or treatment of muscle wasting associated to pathological or age-related conditions.
The present invention relates to the use of a C5aR1 inhibitor for the prevention or treatment of a hypersensitivity reaction (HSR) to a taxane in an individual.
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
71.
CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations excluding the foregoing for use
with blood-related cell processing devices, blood-related
medical and laboratory devices, blood-related software and
technology, or blood-related medical device and data
management systems. Downloadable computer software for use in the identification
of new drugs including with the aid of artificial
intelligence; downloadable computer software for use by
doctors and other medical professionals to acquire, track,
report, analyse health data for use in making informed
medical decisions; downloadable virtual reality software for
medical education; downloadable virtual reality software for
medical screening; downloadable computer software platforms
for use in database management in the field of medicine;
downloadable application software for mobile telephones,
i.e. software to be used in the identification of new drugs;
downloadable computer software using artificial intelligence
to be used in the identification of new drugs; none of the
foregoing for use with blood-related cell processing
devices, blood-related medical and laboratory devices,
blood-related software and technology, or blood-related
medical device and data management systems. Software as a service (SAAS) with software using artificial
intelligence for the identification of new drugs; provision
non-downloadable web-based software for using artificial
intelligence for use in the identification of new drugs;
research in the field of artificial intelligence; design and
development of computer software in the field of medicine;
design and development of virtual reality software for
medical screening; design and development of software for
medical education.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations; disinfectants for hygiene. Downloadable computer software for use in the identification
of new drugs also using artificial intelligence;
downloadable computer software for use by doctors and other
medical professionals to acquire, track, report, analyse
health data for use in making informed medical decisions;
downloadable virtual reality software for medical teaching;
downloadable virtual reality software for medical screening;
downloadable computer software platforms for use in database
management in the field of medicine; downloadable
application software for mobile phones, namely software for
use in the identification of new drugs. Software as a service (SAAS) services with software using
artificial intelligence for the identification of new drugs;
provision of non-downloadable software using artificial
intelligence for use in the identification of new drugs via
a website; research in the field of artificial intelligence;
design and development of computer software in the field of
medicine; design and development of virtual reality software
for medical screening; design and development of software
for medical education.
75.
NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES
The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.
The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
The present invention relates to a pharmaceutical package comprising a plastic container and an aqueous formulations of nerve growth factor (NGF), in which at least the surface of the container in contact with the NGF aqueous formulation is made of particular polypropylenes (PPs), characterized by certain thermal properties and crystallinity. Advantageously said containers show a NGF adhesion significantly lower than that of siliconized glass or of other polypropylenes. It is thus possible to store aqueous formulations of NGF in less severe conditions, avoiding additional coating treatments to the containers and additives while keeping the NGF titer constant.
The present invention relates to a pharmaceutical package comprising a plastic container and an aqueous formulations of nerve growth factor (NGF), in which at least the surface of the container in contact with the NGF aqueous formulation is made of particular polypropylenes (PPs), characterized by certain thermal properties and crystallinity. Advantageously said containers show a NGF adhesion significantly lower than that of siliconized glass or of other polypropylenes. It is thus possible to store aqueous formulations of NGF in less severe conditions, avoiding additional coating treatments to the containers and additives while keeping the NGF titer constant.
The invention relates to IL-17A binding peptides, inhibitors of the interaction of IL-17A with the receptor IL-17RA, and to bioconjugates, dimers, pharmaceutical compositions and medical use thereof.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for the treatment of eye diseases, of pain, of febrile states and influenza, of muscle diseases, of diabetes, of the consequences of organ transplants, of tumors, of gastrointestinal diseases; disinfectants for hygiene Downloadable computer software for use in the identification of new drugs also using artificial intelligence; downloadable computer software for use by doctors and other medical professionals to acquire, track, report, analyse health data for use in making informed medical decisions; downloadable virtual reality software for medical teaching; downloadable virtual reality software for medical screening; downloadable computer software platforms for use in database management in the field of medicine; downloadable application software for mobile phones, namely, software for use in the identification of new drugs Software as a service (SAAS) services with software using artificial intelligence for the identification of new drugs; provision of on-line non-downloadable software using artificial intelligence for use in the identification of new drugs via a website; research in the field of artificial intelligence; design and development of computer software in the field of medicine; design and development of virtual reality software for medical screening; design and development of software for medical education
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparation for the treatment of respiratory diseases; pharmaceutical preparation for the treatment of bone diseases; analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; anti-epileptic pharmaceutical preparations; balms for pharmaceutical purposes; capsules sold empty for pharmaceuticals; cardiovascular pharmaceutical preparations; ocular pharmaceuticals; pharmaceutical products for ophthalmological use; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for the prevention and treatment of rare ocular disorders or diseases; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical antitussive cold preparations; pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in the treatment of rare tissue and organ transplantation-related diseases and conditions; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations, namely, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations, namely, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems Downloadable computer software for use in identifying new drugs; downloadable computer software for use by doctors and other medical professionals in capturing, tracking, reporting, analyzing health data for use in making informed medical decisions; downloadable virtual reality software for medical teaching; downloadable virtual reality software for medical screening; downloadable computer software platforms for use in database management in the field of medicine; downloadable computer application software for mobile phones, namely, software for use in identifying new drugs; downloadable computer software using artificial intelligence for use in identifying new drugs; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems Software as a service (SAAS) services featuring software using artificial intelligence for use in identifying new drugs; providing a website featuring non-downloadable software using artificial intelligence for use in identifying new drugs; research in the field of artificial intelligence; design and development of computer software in the field of medicine; design and development of virtual reality software for medical screening; design and development of virtual reality software for medical teaching, none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems
The present invention relates to a peptide, or derivative thereof, having length equal to or lower than (30) amino acids, and comprising any one of SEQ ID Nos. 2, 3, 9, 10, 13, 14, 15, 16, 17, 18, or a conservative variant thereof, for use as a medicament, preferably for use in the treatment of conditions associated to/caused by deficient angiogenesis or conditions beneficing from increased angiogenesis.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/155 - Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
The present invention refers to a co-crystal of Ketoprofen Lysine named Form 1, a pharmaceutical composition comprising said co-crystal, a process for its production and to its use in the treatment of pain and inflammatory diseases.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to a peptide, or derivative thereof, having length equal to or lower than (30) amino acids, and comprising any one of SEQ ID Nos. 2, 3, 9, 10, 13, 14, 15, 16, 17, 18, or a conservative variant thereof, for use as a medicament, preferably for use in the treatment of conditions associated to/caused by deficient angiogenesis or conditions beneficing from increased angiogenesis.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to a peptide of 14 amino acids having the sequence ID No. 1 or peptide of up to 16 amino acids having a sequence with at least 85%, preferably at least 90%, and preferably at least 95% identity with sequence ID No. 1, or a derivative and/or salt thereof, capable of promoting skin pigmentation and/or innervation in skin dyschromia and/or de-innervation diseases. A pharmaceutical composition comprising such peptide and at least one pharmaceutically acceptable excipient are a further object of the invention.
Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Object of the present invention is a drug delivery system comprising a decellularized corneal stroma scaffold having dispersed within and/or bound to its surface microparticles containing at least one pharmaceutically active molecule dispersed in a matrix having a composition consisting for at least 70% of polylactic co-glycolic acid (PLGA).
Object of the present invention is a drug delivery system comprising a decellularized corneal stroma scaffold having dispersed within and/or bound to its surface microparticles containing at least one pharmaceutically active molecule dispersed in a matrix having a composition consisting for at least 70% of polylactic co-glycolic acid (PLGA).
Research Institute at Nationwide Children's Hospital (USA)
Inventor
Roberts, Ryan David
Brandolini, Laura
Abstract
The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of some sarcomas, preferably in the treatment and/or prevention of osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof.
C07C 311/03 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 311/08 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The present invention relates to a new co-crystal of Ketoprofen, Lysine and Gabapentin, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
97.
"CO-CRYSTAL OF KETOPROFEN, LYSINE AND GABAPENTIN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE"
The present invention relates to a new co-crystal of Ketoprofen, Lysine and Gabapentin, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
98.
"SYNERGISTIC ADMIXTURES OF GABAPENTIN AND KETOPROFEN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE"
The present invention relates to a synergistic admixture of Gabapentin and Ketoprofen, preferably Ketoprofen Lysine, to a pharmaceutical composition comprising said admixtures and to the use of said admixtures or pharmaceutical compositions in the treatment of acute or chronic pain, in particular in the treatment of neuropathic or inflammatory pain.
The present invention relates to a new co-crystal of Gabapentin, Ketoprofen and Lysine, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
The present invention relates to a new co-crystal of Gabapentin, Ketoprofen and Lysine, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
